A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). - Wikidata - wikimedia - TriplyDB

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

http://www.wikidata.org/entity/Q33411920

about

New perspectives in glioblastoma antiangiogenic therapy The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review Development of targeted therapies in treatment of glioblastoma Validation Study: Response-Predictive Gene Expression Profiling of Glioma Progenitor Cells In Vitro Current status and future directions of anti-angiogenic therapy for gliomas Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo Early monitoring antiangiogenesis treatment response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT imaging.Resistance to antiangiogenic therapy.The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.Predictive biomarkers investigated in glioblastoma.Treating recurrent glioblastoma: an update.Novel chemotherapeutics and other therapies for treating high-grade glioma.Glioblastoma targeted therapy: updated approaches from recent biological insights.Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment.Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma.Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.CME Part 1: Hair disorders in cancer patients.Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.[Treatment of the glioma microenvironment].Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme Drug Repurposing of Metabolic Agents in Malignant Glioma

P2860

Q26746028-70889315-3DAB-4725-9E8C-5258D6E32007 Q26752321-AABEDEB1-2A5B-464C-A6DB-0A441E8E96A4 Q26778787-F89D1E47-902A-4A7D-86CC-383F455CC830 Q35957639-B48A7B06-158D-4846-937F-E711F34733E8 Q36618235-E5FDA4DC-1E2D-4587-A0E3-A308FE3C1AD9 Q36962825-B28C96AA-E698-411D-8665-670FC720C1A5 Q37725493-7596398F-162B-4931-8E3B-B7CFAF6E20DB Q38197943-565BCAE6-7CFE-4302-9C1E-EF1463932481 Q38210665-961027DE-5863-4C44-B17E-8747552E6C68 Q38237337-04C9281D-1719-4491-B370-24825D48B13D Q38376610-D08639C5-E4AB-440E-8FC9-76A5934391CB Q38569802-7BD35A94-E7FF-4FED-8A17-88A471E6391D Q38597700-DF917030-7BD6-4359-9F97-C114B56E4F89 Q38627885-F98D5863-8C22-4F3C-9879-AFC9B49B600F Q38676891-19E77F0E-2289-4DBA-8528-94DDFC12C229 Q38776701-F2D64956-FE64-4C0C-B5EC-58EB50B5D53B Q41857963-59FE3E9C-BDFC-4E85-9838-FD783C16BF2C Q42396777-F0A0489A-9623-4076-9B04-248B24DB7046 Q43424854-525E09F3-1D21-4D3A-83D2-8F7E8C4D7DD1 Q48228251-B23A0D88-6737-4E82-A149-8BE518469414 Q52585556-F8364FBA-D835-4B9E-93A1-16FFEA138479 Q54313994-359427A9-B67C-485D-97DD-40E87F068B1F Q55460052-895A6EF5-D554-49B4-9115-D6BE1E68A2F8 Q57141680-FA7E8FC7-6144-4398-8CA9-9D5F4E5D6EA7 Q58738611-1F67F683-2088-41D7-AAFF-FB9975CFF4A2

P2860

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

http://www.wikidata.org/entity/Q33411920

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

A single-arm phase II Austrian ...... irst recurrence (SURGE 01-07).

@ast

A single-arm phase II Austrian ...... irst recurrence (SURGE 01-07).

@en

type

label

A single-arm phase II Austrian ...... irst recurrence (SURGE 01-07).

@ast

A single-arm phase II Austrian ...... irst recurrence (SURGE 01-07).

@en

prefLabel

A single-arm phase II Austrian ...... irst recurrence (SURGE 01-07).

@ast

A single-arm phase II Austrian ...... irst recurrence (SURGE 01-07).

@en

P1433

Q33411920-E7331933-AE50-4DC5-A429-AF42F978D2E0

P1476

Q33411920-312F737B-1428-4D28-952E-731BA539EF92

P2093

Q33411920-0E014A41-28F5-400B-B0B2-7FC7C0FD7B95

Q33411920-1BA5DE99-4008-4C82-B067-46BF077116BC

Q33411920-30DB0CA4-9D06-475F-8315-E4C5870256C7

Q33411920-4D9436C1-5AA2-4542-B8EB-2E0E17EC4B8A

Q33411920-67329048-33E1-4B83-A5CE-F4B748858FDE

Q33411920-6AB5FA66-85E8-4DB5-A6E4-5DEC09BD9EE4

Q33411920-6BC34135-20DF-4055-BE1C-511B30D4A462

Q33411920-8C61368B-FD97-44C6-99D8-2544F0586082

Q33411920-9E0AFE1D-CCE4-4C33-9913-50E9585F703A

Q33411920-B989A146-68F9-4A60-A0A4-86510011B372

P2860

Q33411920-08074B73-505D-4F16-98CE-AFCDF0A7E23C

Q33411920-19690A37-569B-4D3E-9716-24208F0175BE

Q33411920-1F19FFBB-9CC6-4F55-BB38-85485E999FCF

Q33411920-2634EB8E-4C5C-4660-AE3F-B5622CDFEAC0

Q33411920-2E837399-3C1F-4519-AF1F-530B3FD762E0

Q33411920-2E84E37A-EC22-4001-AA73-8CC542833CFA

Q33411920-49B82AC8-5860-48BE-BBCA-0D4B67FD76FB

Q33411920-4D7B6490-915C-44AF-B62F-E3A5440762D9

Q33411920-4DD7C5B9-BCED-4EB3-A426-81D84E912B4D

Q33411920-4F901361-5326-4551-B89E-6E4540693BD8

P304

Q33411920-F776B958-326F-477E-8DA9-9A647D5DDA39

P31

Q33411920-E1B3A1BB-B463-4210-8DED-5E41D2579BFC

P356

Q33411920-71F78B8A-68FE-446D-B59A-E3D5D3496043

P433

Q33411920-72D0BF89-7E69-4B34-BCBC-1CF0D1A3A38F

P478

Q33411920-A6BD1704-664D-45C8-9F0F-8C838DC966EB

P50

Q33411920-09C7A080-3CE6-4ED7-AA7B-1DACA9A4F8AB

Q33411920-328A0516-55F6-46C1-887B-FDF7E3B7F3A2

Q33411920-56FA7123-BCBC-4A02-8781-C4749D294ADB

Q33411920-5FFC100A-5159-468D-BFA2-951FA1A7F46C

Q33411920-C0A764BB-800B-46BA-BE79-694A3E33C89A

P577

Q33411920-8CD71DB9-79EA-4CEE-B64C-D4699D6033DA

P698

Q33411920-FE807D03-440E-472C-A3C5-CAD3C5AB41ED

P921

Q33411920-B06BF6E9-D88F-4D06-99B0-F061C6774FAF

Q33411920-FD8B38D0-8864-4606-A2D0-A7532272DFB9

P932

Q33411920-8A988882-9173-4FBD-B93A-2FC2B4FE3D74

P356

P1433

P1476

A single-arm phase II Austrian ...... irst recurrence (SURGE 01-07).

@en

P2093

Antje Wick

http://www.w3.org/2001/XMLSchema#string

Bernhard Holzner

http://www.w3.org/2001/XMLSchema#string

Christine Marosi

http://www.w3.org/2001/XMLSchema#string

Günther Stockhammer

http://www.w3.org/2001/XMLSchema#string

Jochen Tuettenberg

http://www.w3.org/2001/XMLSchema#string

Johanna Buchroithner

http://www.w3.org/2001/XMLSchema#string

Johannes Haybaeck

http://www.w3.org/2001/XMLSchema#string

Marcel Seiz

http://www.w3.org/2001/XMLSchema#string

Markus Hutterer

http://www.w3.org/2001/XMLSchema#string

Martin Moik

http://www.w3.org/2001/XMLSchema#string

P2860

Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population.

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Phase II study of sunitinib malate in patients with recurrent high-grade glioma.

P304

92-102

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOT161

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Preusser

Martha Nowosielski

Florian Stockhammer

P577

2013-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24311637

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multicenter trial

P932

3870838

http://www.w3.org/2001/XMLSchema#string